| Investigation item |
All patients
(N=100) |
GERD(+) (n=28) |
GERD(-)
(n= 72) |
P-value |
| Age(year) |
69.3±8.9 |
66.9±9.4 |
70.3±8.6 |
0.88 |
| Gender(male/female) |
59/41 |
17/11 |
42/30 |
1.00 |
| Height(cm) |
159.3±7.7 |
160.8±8.5 |
158.7±7.3 |
0.24 |
| Body weight(kg) |
62.8±10.1 |
67.8±12.8 |
60.2±9.1 |
0.02 |
| Stroke type(A/L/C/T) |
34/49/14/3 |
11/13/2/2 |
23/36/12/1 |
0.27 |
| SBP(mmHg) |
129.0±13.1 |
127.4±10.6 |
129.6±13.9 |
0.06 |
| DBP(mmHg) |
75.0±10.3 |
74.8±10.5 |
75.1±10.3 |
0.99 |
| PR(/min) |
69.7±10.8 |
70.5±10.4 |
69.4±11.0 |
0.46 |
| Hypertension (%) |
88(88) |
23(82) |
65(90) |
0.31 |
| ARBs (%) |
63(63) |
13(46) |
50(69) |
0.04 |
| CCBs (%) |
73(73) |
19(68) |
54(75) |
0.47 |
| Diuretics (%) |
15(15) |
1(4) |
14(19) |
0.06 |
| ACEIs (%) |
5(5) |
2(7) |
3(4) |
0.62 |
| Beta blockers (%) |
7(7) |
2(7) |
5(7) |
1.00 |
| Alfa blockers (%) |
7(7) |
2(7) |
5(7) |
1.00 |
| Dyslipidemia (%) |
73(73) |
13(64) |
55(76) |
0.32 |
| Statins (%) |
71(71) |
19(68) |
52(72) |
0.81 |
| Ezetimib (%) |
2(2) |
0(0) |
2(3) |
1.00 |
| EPA (%) |
12(12) |
1(4) |
11(15) |
0.17 |
| DM (%) |
38(38) |
14(50) |
24(33) |
0.17 |
| SUs (%) |
13(13) |
4(14) |
9(13) |
0.75 |
| DPP4 inhibitors (%) |
24(24) |
10(36) |
14(19) |
0.12 |
| TDs (%) |
13(13) |
4(14) |
9(13) |
0.75 |
| α-GIs (%) |
7(7) |
2(7) |
5(7) |
1.00 |
| Insulin (%) |
2(2) |
1(4) |
1(1) |
0.48 |
| Current smoking |
5(5) |
0(0) |
5(7) |
0.32 |
Values are mean ± standard deviation. Stroke type (A/L/C/T), atherothrombotic
stroke/lacunar stroke, cardioembolic stroke/TIA; SBP, systolic blood pressure;
DBP, diastolic blood pressure; PR, pulse rate; ARBs, angiotensin receptor
blockers; CCBs, calcium channel blockers; ACEIs, angiotensin converting enzyme
inhibitors; SUs, sulfonylureas; DPP4 inhibitors, dipeptidyl Peptidase-4 inhibitors;
TDs, thiazolidine derivatives; α-GIs, alfa-glycosidase inhibitors. |
